Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside | The Motley Fool

Ken Griffin's Citadel has significantly increased its investment in AbbVie by over 500%, signaling a strategic shift towards defensive stocks amid market volatility. With a robust 2.6% dividend yield and a strong business foundation, including new drug developments and a solid aesthetics segment, AbbVie presents a compelling...